Literature DB >> 27168138

Recurrence patterns of mucose-associated lymphoid tissue lymphoma after definitive radiation treatment: A single center experience.

Ji Hyeon Joo1, Sang-Wook Lee1, Jooryung Huh2, Cheolwon Suh3, Dok Hyun Yoon3, Seung Do Ahn1, Eun Kyung Choi1, Jong Hoon Kim1.   

Abstract

OBJECTIVES: To evaluate the treatment outcomes in non-gastric and non-nodal mucose-associated lymphoid tissue (MALT) lymphoma patients treated by definitive radiation therapy (RT).
METHODS: A total of 134 patients were analyzed. The RT dose was 30.6 or 36 Gy.
RESULTS: The median follow-up duration for all patients was 51.1 months (range, 3.0-132.4 months). Among the 88 orbital MALT lymphoma patients, 12 had disease recurrence. There were 23 head and neck tumor patients. Two patients experienced relapse, all at out-of-field locations. Gastrointestinal MALT lymphoma was diagnosed in 13 patients, and three showed local (n = 1), distant (n = 1), or local/distant (n = 1) relapse.
CONCLUSION: RT alone is highly effective in achieving local control and long-term survival in localized MALT lymphoma. In orbital MALT, excellent local control is achieved, and relapse is predominantly observed in the contralateral eye. Other head and neck lymphomas are also well controlled.

Entities:  

Keywords:  Lymphoma; MALT; Radiotherapy; Recurrences

Mesh:

Year:  2016        PMID: 27168138     DOI: 10.1080/10245332.2016.1164933

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  2 in total

1.  Prospective Study of 4 Gy Radiotherapy for Orbital Mucosa-Associated Lymphoid Tissue Lymphoma (FORMAL).

Authors:  Jaehyeon Park; Ji Woon Yea; Se An Oh; Min Kyoung Kim; Jun Hyuk Son; Jae Won Park
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

2.  Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas.

Authors:  Jonathan Baron; Christopher M Wright; Daniel Y Lee; Maribel Carpenter; Shwetha H Manjunath; César A Briceño; Elise Chong; Amit Maity; John P Plastaras; Ima Paydar
Journal:  Front Oncol       Date:  2021-07-05       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.